Royalty Pharma (RPRX) revenue and earnings history
Royalty Pharma reported revenue of $2.38B for fiscal 2025 (year ended Dec 31, 2025), +5.1% on the year before, and net income of $771M.
Over 7 years, from fiscal 2018 to fiscal 2025, revenue grew at a compound rate of +4.1% a year.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $2.38B+5.1% | $1.56B | $771M | $2.49B | — | — | $290M | $1.23B | — | $619M | $8.95B | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Royalty Pharma (RPRX) on OQRO.
Common questions
What was Royalty Pharma's revenue in fiscal 2025?
$2.38B for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 11, 2026. That is +5.1% on fiscal 2024 ($2.26B).
How fast has Royalty Pharma's revenue grown?
From $1.79B in fiscal 2018 to $2.38B in fiscal 2025: a compound annual growth rate of +4.1% over 7 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Royalty Pharma been profitable?
Yes, in every one of the 8 fiscal years shown. The highest net income was $2.35B in fiscal 2019.
Where these figures come from
The SEC’s companyfacts data: every figure Royalty Pharma tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
